177 results about "Dermal fibroblast" patented technology

Three-dimensional tissue-like organization of cells by high cell-seeding-density culture termed as macromass culture is described. By macromass culture, cells can be made to organize themselves into a tissue-like form without the aid of a scaffold and three-dimensional macroscopic tissue-like constructs can be made wholly from cells. Tissue-like organization and macroscopic tissue-like constructs can be generated from fibroblastic cells of mesenchymal origin (at least), which can be either differentiated cells or multipotent adult stem cells. In this work, tissue-like organization and macroscopic tissue-like constructs have been generated from dermal fibroblasts, adipose stromal cells-derived osteogenic cells, chondrocytes, and from osteoblasts. The factor causing macroscopic tissue formation is large scale culture at high cell seeding density per unit area or three-dimensional space, that is, macromass culture done on a large scale. No scaffold or extraneous matrix is used for tissue generation, the tissues are of completely cellular origin. No other agents (except high cell-seeding-density) that aid in tissue formation such as tissue-inducing chemicals, tissue-inducing growth factors, substratum with special properties, rotational culture, etc, are employed for tissue formation. These tissue-like masses have the potential for use as tissue replacements in the human body. Tissue-like organization by high cell-seeding-density macromass culture can also be generated at the microscopic level.

A composition is disclosed for treating the skin comprising an acylated short chain bioactive peptide and Lycium barbarum extract product. Also disclosed is a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The composition may contain dimethylisosorbide or ethoxydiglycol as solubilizing and penetration enhancers for the hydrophobically modified peptide.

Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells / mL.

Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×107 cells / mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.

An autologous topical formulation containing conditioned medium obtained from culture of autologous fibroblasts has been developed. Unlike other topical formulations, it is autologous since it is derived solely from cells obtained by the person who is to use the formulation. This avoids any possible reaction with proteins derived from the cells. Preferred formulations include gels, creams, lotions, and ointments. The topical formulations of conditioned medium obtained by culturing autologous dermal fibroblasts are topically administered to individuals for the prevention and treatment of scarring, reduction in signs of aging, and improvement in quality of skin.

A composition is disclosed for treating the skin comprising an acylated short chain bioactive peptide and Lycium barbarum extract product. Also disclosed is a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The composition may contain dimethylisosorbide or ethoxydiglycol as solubilizing and penetration enhancers for the hydrophobically modified peptide.

The present inventors revealed for the first time in the world that 1) a large amount of bone marrow-derived cells are mobilized in transplanted skin; 2) the mobilized bone marrow-derived cells are differentiated into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells and epidermal keratinocytes in a transplanted skin graft, and in the mobilized bone marrow-derived cells, bone marrow-derived mesenchymal stem cells are contained; 3) what mobilize the bone marrow-derived mesenchymal stem cells to the graft from the peripheral blood are HMGB1, HMGB2 and HMGB3 released from necrotic tissue of the transplanted skin; 4) purified HMGB1, HMGB2 and HMGB3 promote migration of mesenchymal stem cells isolated from the bone marrow and cultured; 5) active substances including HMGB1 that allow bone marrow mesenchymal stem cells to migrate can be simply purified from an extract of a large number of organs including skin, brain and heart; 6) active substances that allow bone marrow mesenchymal stem cells to migrate can be simply extracted from cultured cells; and 7) a heparin column-purified fraction of skin extract mobilizes a large amount of bone marrow-derived cells during brain damage.

One purpose of the invention is to provide a method and a formula, which is characterized in that mesenchymal stem cells from an autologous fat cell tissue are proliferated by in-vitro culture, then is mixed into a support material and finally is transplanted into the body of a patient; the fat mesenchymal cell in a transplant is differentiated to derma fibroblast under the action of the local microenvironment, the newly generated derma fibroblast can further activate secretion of cell collagenstroma at an injection part so as to carry out reproductive repair on coloboma and aging of human skin tissue. The application scope of the invention includes: subcutaneous padding for face lift, subcutaneous padding cosmetology, subcutaneous padding for repairing depressed deletion or impairment and the like. Seed cells utilized in the invention are prepared by separating and purifying the fat tissues of the patients, so that ethical disputes and immunological rejection reaction are avoided. The fat tissues can be obtained by the instrument suction method; and the operation of the method is simple, patients suffer from minor damages and pains.

Three-dimensional tissue-like organization of cells by high cell-seeding-density culture termed as macromass culture is described. By macromass culture, cells can be made to organize themselves into a tissue-like form without the aid of a scaffold and three-dimensional macroscopic tissue-like constructs can be made wholly from cells. Tissue-like organization and macroscopic tissue-like constructs can be generated from fibroblastic cells of mesenchymal origin (at least), which can be either differentiated cells or multipotent adult stem cells. In this work, tissue-like organization and macroscopic tissue-like constructs have been generated from dermal fibroblasts, adipose stromal cells-derived osteogenic cells, chondrocytes, and from osteoblasts. The factor causing macroscopic tissue formation is large scale culture at high cell seeding density per unit area or three-dimensional space, that is, macromass culture done on a large scale. No scaffold or extraneous matrix is used for tissue generation, the tissues are of completely cellular origin. No other agents (except high cell-seeding-density) that aid in tissue formation such as tissue-inducing chemicals, tissue-inducing growth factors, substratum with special properties, rotational culture, etc, are employed for tissue formation. These tissue-like masses have the potential for use as tissue replacements in the human body. Tissue-like organization by high cell-seeding-density macromass culture can also be generated at the microscopic level.

The invention discloses an organ engineering tendon graft which comprises (a) biodegradable materials which can be accepted in pharmacy; (b) seed cells which can be inoculated to the biodegradable materials, and the seed cells are selected from the following groups: (i) fibroblasts, (ii) adipose-derived cells, or (iii) the mixture of the dermal fibroblasts and the adipose-derived cells with the ratio of 1:10000 to 10000:1. The graft is gotten from the cultivation of a complex of the seed cells and the biodegradable materials in a bioreactor, and the complex is obtained through the mixing of the seed cells and the biodegradable materials which can be accepted in pharmacy. The graft can be used for restoring the tendon defect.

A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90α or the middle domain plus the charged sequence of hsp90α. The composition is topically applied to skin wounds, covering the outer surface of the wound. The heat shock protein acts by promoting migration of both human epidermal keratinocyte and dermal fibroblasts to the wound in order to close, heal, and remodel the wound.

The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.

The invention discloses a starfish extract used for preparing a composition for promoting the collagen proliferation, which comprises a variety of active ingredients used for effectively improving the collagen generation capability of dermal fibroblasts cells. Meanwhile, the extraction method of the invention is capable of improving the economic worth of a starfish and is pollution-free. Meanwhile, the starfish extract can be effectively applied to skin-care products and cosmetics.